Oxbryta (Voxelotor)

Voxelotor, the active ingredient in Oxbryta, is a hemoglobin oxygen-affinity modulator presented as a 1500 mg tablet for oral use. It is indicated for the treatment of sickle cell disease in adults and pediatric patients aged six years and older. GNH USA supplies Oxbryta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxbryta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxbryta is used to manage sickle cell disease, a genetic disorder that affects hemoglobin function.

- Sickle cell disease: Improves hemoglobin oxygen affinity, reducing red blood cell sickling and hemolysis. - Chronic anemia associated with sickle cell disease: Increases hemoglobin levels and reduces transfusion requirements. - Vaso‑occlusive complications: Lowers the frequency of pain crises and related hospitalizations.

Adverse reactions reported with Oxbryta are generally mild to moderate.

Common Side Effects: - Headache - Diarrhea - Nausea - Fatigue - Decreased appetite - Upper respiratory tract infection

Serious or Rare Side Effects: - Severe anemia - Acute chest syndrome - Hepatotoxicity (elevated liver enzymes) - Hypersensitivity reactions - Thromboembolic events - Priapism

When prescribing Oxbryta, clinicians should consider several safety aspects.

- Baseline hemoglobin monitoring: Perform at initiation and periodically thereafter. - Liver function tests: Assess before treatment and during therapy. - Renal function: Evaluate in patients with moderate to severe impairment. - Concomitant hemolytic agents: Avoid co‑administration with drugs known to increase hemolysis. - Pregnancy and lactation: Use only if the potential benefit outweighs the risk. - Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture.

Oxbryta may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may lower voxelotor exposure. - Concomitant use with other hemoglobin‑modifying agents – risk of additive hematologic effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole) – may increase voxelotransfer‑related exposure. - Anticoagulants (warfarin, DOACs) – monitor coagulation parameters. - NSAIDs – observe for gastrointestinal bleeding risk. - Hydroxyurea – assess for combined hematologic impact.